ERBB2 and inflammatory breast carcinoma: A phase II study comparing lapatinib (1500 mg) in combination with either placebo or pazopanib (800 mg) in patients with relapsed HER2-positive inflammatory breast cancer (IBC) was reported at 2012 ASCO annual meeting.